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Abstract
Background: We aimed to assess associations between circulating IL-18 concentrations
and cardiovascular outcomes in patients with acute coronary syndromes (ACS).
Hypothesis and Methods: Plasma IL-18 concentrations were measured at admission,
discharge, 1 month, and 6 months in patients with ACS in the PLATelet inhibition
and patient Outcomes (PLATO) trial. Associations with outcomes were evaluated
with Cox regression models on the composite of CV death, spontaneous myocardial
infarction (sMI), or stroke; and on CV death or sMI separately, including adjustment
for clinical risk factors and biomarkers (cTnT-hs, NT-proBNP, cystatin C, CRP-hs, and
GDF-15).
Results: Median IL-18 concentrations at baseline, discharge, 1 month, and 6 months
were 237, 283, 305, and 320 ng/L (n = 16 636). Male sex, obesity, diabetes, and
plasma levels of cystatin C, GDF-15, and CRP-hs were independently associated with
higher IL-18 levels. Higher baseline IL-18 levels were associated with the composite
endpoint and with CV death (hazard ratio [HR] 1.05, 95% confidence interval
[95% CI] 1.02-1.07 and HR 1.10, 95% CI 1.06-1.14, respectively, per 25% increase of
IL-18 levels). Associations remained significant after adjustment for clinical variables
but became non-significant after adjustment for all biomarkers (HR 1.01, 95%
CI 0.98-1.04 and HR 1.04, 95% CI 1.00-1.08, respectively). There were no associa-
tions with sMI.
Conclusions: In ACS patients, IL-18 concentrations increased after the acute event
and remained increased for 6 months. Baseline IL-18 levels were significantly associ-
ated with CV mortality, independent of clinical characteristics and indicators of
renal/cardiac dysfunction but this association was attenuated after adjustment for
multiple biomarkers.
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1 | INTRODUCTION
Inflammation is important for the development of atherosclerosis and
inflammatory mediators synergistically amplify traditional risk factors
of cardiovascular (CV) disease.1 An increased inflammatory activity is
associated with progression of stable coronary disease but also the
future risk of acute coronary syndromes (ACS).1-3 The role of inflam-
matory mediators in ACS is however less understood and routine
measurement of inflammatory markers is not supported by interna-
tional guidelines.4
Interleukin-18 (IL-18), a member of the IL-1 cytokine superfamily,
is a pleiotropic inflammatory cytokine expressed in several cells
including macrophages and endothelial cells.5 Increased circulating
IL-18 concentrations have been associated with coronary artery
disease and an increased risk for cardiovascular (CV) morbidity and
mortality.6,7 IL-18 has been detected in atherosclerotic plaques and
has been proposed to destabilize coronary plaques leading to subse-
quent thrombotic events.3 Nonetheless, the importance of circulating
IL-18 in patients with ACS is not well documented.8
The PLATelet inhibition and patient Outcomes (PLATO) trial included
patients with ST-elevation and non-ST-elevation ACS, and showed that
ticagrelor was superior to clopidogrel treatment in preventing CV mortal-
ity, myocardial infarction (MI), or stroke.9,10 In the current biomarker
substudy, we aimed to (a) evaluate the association between IL-18 concen-
trations and CV outcomes and bleeding and (b) explore the IL-18 concen-
trations during follow-up, and (c) assess possible interactions with
randomized treatment (ticagrelor or clopidogrel).
2 | MATERIALS AND METHODS
2.1 | Design and study population
The global, randomized, placebo-controlled PLATO trial enrolled 18 624
patients with either ST-elevation ACS or non-ST-elevation ACS (Clinical
Trial Registration: ClinicalTrials.gov NCT00391872).9,10 The enrolled
patients received optimal medical therapy including aspirin, and optional
invasive strategy, and were randomized to either clopidogrel or ticagrelor
treatment.9,10 The patients were recruited between October 2006 and
July 2008 and were subject to blood sampling as a part of a predefined
biomarker substudy program.9,10 The overall aims and details of the bio-
marker substudy program have previously been presented.9 All partici-
pants provided written informed consent and the study complied with
the declaration of Helsinki. The study was approved by all local Ethics
Committees and Institutional Review Boards.
2.2 | Endpoint definition
The pre-specified primary composite endpoint of the present substudy
was the combination of CV death, stroke or spontaneous MI (sMI)
within 1 year of follow-up.11 CV death and sMI were also separately
evaluated, and secondary outcomes also included PLATO-defined non-
CABG major bleeding.9 Stroke was not separately evaluated, due to
few events. All endpoints in the PLATO trial were centrally adjudicated
by an independent and blinded clinical event adjudication committee in
order to sub classify causes of death and to subdivide types of myocar-
dial infarctions, stroke, and bleeding events.9,11 CV death was defined
as sudden death or death with no clear attributable non-cardiovascular
cause. Spontaneous myocardial infarction was defined in accordance
with the universal definition of myocardial infarction, hence a non-pro-
cedural, non-fatal, MI type 1.11 The definition of stroke has previously
been described.9
PLATO major bleeding was defined as fatal or intracranial bleeding
or requiring two units of blood transfusion or with a drop in hemoglo-
bin of >5 g/dL.9
2.3 | Sampling and laboratory analysis
Baseline venous blood samples were obtained at the time of randomi-
zation within 24 hours of admission, and prior to the administration of
study medication. In addition, a predefined substudy program with
serial blood sampling was conducted at selected sites in order to
obtain samples from 4000 patients at discharge and after 1 month
after randomization and from at least 3000 of these patients also at
6 months. Patients at these selected sites were continuously invited
to participate in the substudy until it was estimated that at least 3000
patients would be available for blood sampling at 6 months. Patients
with a baseline blood sample and at least one additional blood sample
during follow-up were included in the serial biomarker analyses.
The venous blood was centrifuged and plasma samples were
frozen in aliquots and stored at −70C until analyzed at the Uppsala
Clinical Research Center laboratory, Uppsala, Sweden. Plasma IL-18
levels were measured using MBL human IL-18 ELISA (MBL Medical &
Biological Laboratories Co.). High-sensitivity cardiac troponin T (cTnT-hs,
ng/L), N-terminal pro-B-type natriuretic peptide (NT-proBNP, pmol/L),
and cystatin C were determined with sandwich immunoassays on the
Cobas Analytics e601 Immunoanalyzer (Roche Diagnostics, Mannheim,
Germany).
The growth differentiation factor-15 (GDF-15, ng/L) concentra-
tion was determined with Elecsys electrochemiluminescence immuno-
assay on a Cobas Immunoanalyzer system (Roche Diagnostics,
Rotkreuz, Switzerland).12
White blood cells (WBC) and high-sensitivity C-reactive protein
(CRP-hs) were locally analyzed at site.
2.4 | Statistical analysis
Baseline characteristics were presented by IL-18 strata. Categorical
baseline variables were presented as frequencies and percentages and
compared by quartile groups of IL-18 using χ2 tests. Continuous vari-
ables were presented as medians with the 25th to 75th percentiles
and the comparison between quartile groups of IL-18 used the
Kruskal-Wallis test. IL-18 concentrations were ln transformed to
obtain approximate normal distribution. Correlations between IL-18
and other biomarkers were determined using Spearman's correlation
coefficients.
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Crude event rates at 1-year were estimated by IL-18 quartile
groups. The association between IL-18 concentrations (ln transformed),
on admission, with the composite primary endpoint of CV death, sMI
or stroke, and secondary endpoints of CV death alone, sMI alone and
non-CABG major bleeding were assessed by multivariable Cox propor-
tional hazards models. Similarly, the associations between IL-18 quartile
groups were examined, with the lowest quartile group as reference.
Four multivariable Cox proportional hazard models, with the hazard
per 25% increase of IL-18 level, were used. The first model (model 1)
included only randomized treatment (ticagrelor or clopidogrel). Model
2 added adjustment for baseline clinical risk factors: age, sex, body mass
index (BMI), diabetes, dyslipidemia, history of heart failure, hyperten-
sion, smoking status, type of ACS, chronic kidney disease, planned inva-
sive or non-invasive strategy, previous cardiovascular disease; and
history of myocardial infarction, percutaneous coronary intervention
(PCI), coronary artery bypass grafting (CABG), non-hemorrhagic-stroke,
and peripheral artery disease (PAD). Model 3 included all previous
covariates, with further addition of ln-transformed biomarkers of renal
(cystatin C) and myocardial dysfunction (cTnT-hs and NT-proBNP).
Model 4 included all covariates from model 1-3 with the addition of the
following ln-transformed biomarkers: WBC, CRP-hs, and GDF-15.
The shape of the association between continuous IL-18 and the
hazard ratio for the endpoint of interest was evaluated using
restricted cubic splines with four knots.
The predefined serial measurements of IL-18 were analyzed by
analysis of covariance, with baseline IL-18 and treatment group as
independent variables, separately at each time point. Medians, as well
as geometric means, of IL-18 at the different time points (baseline,
discharge, 1 month, and 6 months) were calculated.
P values less than .05 were considered statistically significant
results. All statistical analyses were performed with SAS 9.4 (SAS
Institute, Cary, North Carolina).
TABLE 1 Baseline characteristics and biomarkers by quartile groups of IL-18 concentrations at baseline
Characteristic Q1 Q2 Q3 Q4
<180.0 ng/L 180.0-237.0 ng/L 237.0-311.0 ng/L >311.0 ng/L P value
n = 4176 n = 4174 n = 4118 n = 4168
Age (y) 63 (55-71) 62 (54-71) 61 (54-70) 61 (53-70) <.0001
Female 1563 (37.4%) 1211 (29.0%) 1019 (24.7%) 964 (23.1%) <.0001
BMI kg/m2 26.9 (24.3-29.7) 27.3 (24.8-30.4) 27.7 (24.9-30.9) 27.8 (25.1-31.0) <.0001
Risk factor
Habitual smoker 1338 (32.0%) 1484 (35.6%) 1526 (37.1%) 1561 (37.5%) <.0001
Hypertension 2749 (65.8%) 2670 (64.0%) 2725 (66.2%) 2734 (65.6%) .1524
Dyslipidemia 2018 (48.3%) 2030 (48.6%) 1917 (46.6%) 1886 (45.2%) .0056
Diabetes mellitus 866 (20.7%) 985 (23.6%) 1045 (25.4%) 1256 (30.1%) <.0001
Medical history
Angina pectoris 1844 (44.2%) 1846 (44.2%) 1804 (43.8%) 1898 (45.5%) .4053
Myocardial infarction 825 (19.8%) 883 (21.2%) 835 (20.3%) 895 (21.5%) .1906
Congestive heart failure 215 (5.1%) 243 (5.8%) 218 (5.3%) 288 (6.9%) .0022
PCI 539 (12.9%) 579 (13.9%) 563 (13.7%) 528 (12.7%) .2985
CABG 265 (6.3%) 239 (5.7%) 224 (5.4%) 251 (6.0%) .3328
TIA 107 (2.6%) 121 (2.9%) 95 (2.3%) 129 (3.1%) .1232
Non-hemorrhagic stroke 141 (3.4%) 159 (3.8%) 165 (4.0%) 165 (4.0%) .4195
Peripheral arterial disease 193 (4.6%) 244 (5.8%) 275 (6.7%) 310 (7.4%) <.0001
Chronic renal disease 133 (3.2%) 157 (3.8%) 181 (4.4%) 220 (5.3%) <.0001
Type of ACS
ST-elevation MI 1630 (39.0%) 1648 (39.5%) 1708 (41.5%) 1733 (41.6%) .0281
Biomarker median (Q1-Q3)
cTnT-hs ng/L 183.0 (43.3-627.0) 189.0 (45.4-636.0) 188.0 (45.0-657.0) 205.0 (48.5-714.0) .0369
NT-proBNP pmol/L 61.9 (20.4-188.1) 55.0 (18.3-169.8) 56.7 (18.4-176.5) 63.3 (19.5-206.1) .0012
GDF-15 pg/L 1411 (1061-1986) 1492 (1121-2099) 1574 (1159-2283) 1731 (1265-2564) <.0001
Cystatin C mg/L 0.76 (0.63-0.92) 0.81 (0.67-0.97) 0.84 (0.69-1.03) 0.90 (0.73-1.13) <.0001
White blood cells 8.80 (7.00-11.10) 9.10 (7.30-11.50) 9.40 (7.50-11.50) 9.30 (7.50-11.90) <.0001
CRP mg/L 2.9 (1.2-6.9) 3.5 (1.5-8.4) 4.1 (1.8-10.0) 5.0 (2.1-13.0) <.0001
Notes: Categorical baseline variables were presented as frequencies and percentages and compared by quartile groups of IL-18 using χ2 tests. Continuous
baseline variables were presented as medians and 25th to 75th percentiles and compared by quartile groups of IL-18 using Kruskal-Wallis tests.
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TABLE 2 Multivariable Cox regression analysis, and event rates, on baseline IL-18 (ng/L) and the primary composite outcome; CV death, sMI
or stroke, during up to 1 year of follow-up (n = 16 636)
Model IL-18 level No of events No of patients Event rate (%) HR (95% CI) P value
Model 1a Continuous 1424 16 636 8.6 1.05 (1.02-1.07) .0003
Model 1b <Q1: <180.0 331 4176 7.9 .0179
Q1-<Q2: 180.0-237.0 346 4174 8.3 1.05 (0.91-1.23)
Q2-<Q3: 237.0-311.0 346 4118 8.4 1.08 (0.93-1.25)
≥Q3: ≥ 311.0 401 4168 9.6 1.25 (1.08-1.44)
Model 2a Continuous 1407 16 577 8.5 1.04 (1.02-1.07) .0017
Model 2b <Q1: <180.0 326 4161 7.8 .0763
Q1-<Q2: 180.0-237.0 343 4162 8.2 1.06 (0.91-1.24)
Q2-<Q3: 237.0-311.0 343 4102 8.4 1.11 (0.95-1.30)
≥Q3: ≥311.0 395 4152 9.5 1.21 (1.04-1.41)
Model 3a Continuous 1380 16 139 8.6 1.03 (1.00-1.05) .0625
Model 3b <Q1: <180.0 313 4052 7.7 .6527
Q1-<Q2: 180.0-237.0 338 4057 8.3 1.07 (0.92-1.25)
Q2-<Q3: 237.0-311.0 338 4008 8.4 1.07 (0.92-1.25)
≥Q3: ≥311.0 391 4022 9.7 1.10 (0.95-1.29)
Model 4a Continuous 1230 14 488 8.5 1.01 (0.98-1.04) .4085
Model 4b <Q1: <180.0 280 3660 7.7 .9427
Q1-<Q2: 180.0-237.0 308 3685 8.4 1.05 (0.89-1.24)
Q2-<Q3: 237.0-311.0 302 3598 8.4 1.02 (0.86-1.20)
≥Q3: ≥311.0 340 3545 9.6 1.03 (0.87-1.21)
Notes: Model 1 includes ln(IL-18) and randomized treatment. Model 2 includes ln(IL-18) and clinical variables. Model 3 includes the covariates from Model 2 and
biomarkers: ln(cystatin C), ln(cTnT-hs), ln(NT-proBNP). Model 4 includes the covariates from Model 3 and biomarkers: ln(CRP), ln(GDF-15), and ln(WBC).
F IGURE 1 Forest plot of the hazard ratios and 95% CIs, per 25% increase in baseline IL-18 level, for the composite endpoint, and for CV
death and spontaneous MI separately during up to 12 months of follow-up
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3 | RESULTS
3.1 | IL-18 concentrations and associations with
baseline characteristics and other biomarkers
Data on baseline IL-18 concentrations were available for 16 636 patients
(89.3%), with a median (interquartile interval) of 237 ng/L (180.0-311.0)
ng/L (Table 1). The IL-18 concentrations spanned between 12.5 and
33 180 ng/L with a mean of 276 ng/L and an SD of ±436 ng/L.
Baseline characteristics in association to levels of other bio-
markers by IL-18 quartile groups are presented in Table 1. Lower age,
male sex, greater weight and body mass index, diabetes and decreased
kidney function were all associated with increased IL-18 concentra-
tions (Table 1). There were also associations between increased IL-18
levels and increased levels of NT-proBNP, cystatin C, GDF-15, white
blood cells and the inflammatory markers CRP-hs, IL-6, and IL-10.
However, Spearman correlation coefficients between IL-18 and other
ln-transformed biomarkers revealed limited associations with the
highest correlation coefficients for CRP-hs of 0.166 and for GDF-15
of 0.164.
The variables significantly associated with increasing IL-18 con-
centration at baseline were male sex, age, diabetes, BMI > 30 kg/m2
and increasing levels of the biomarkers NT-proBNP, cTnT-hs, CRP-hs,
and cystatin C (Table 1).
3.2 | Associations with outcomes
The primary endpoint, the combination of CV death, stroke or sMI, was
observed in 1424 (8.6%) patients. Crude event rates, by quartile groups
of IL-18 concentration, for the composite endpoint were 7.9%, 8.3%,
8.4%, and 9.6% (Table 2, Figure 1). The unadjusted hazard ratio (HR), per
25% increase in IL-18 concentration, was HR 1.05 (95% CI 1.02-1.07).
After the addition of clinical variables and biomarkers, the multivariable
adjusted HR was 1.01 (95% CI 0.98-1.04) (Table 2, Figure 1).
Event rates for CV death alone per increasing quartile groups of IL-
18 were 3.2%, 3.4%, 4.4%, and 5.3% (Table 3). Multivariable adjusted HR
per 25% increase in IL-18 concentration on CV death was significantly
associated with outcome, even after the adjustment for randomized
treatment, clinical variables and the biomarkers cystatin C, cTnT-hs, and
NT-proBNP. However, after additional adjustment with the biomarkers
WBC, GDF-15 and CRP-hs in model 4, the association between IL-18
and CV death was insignificant (Table 3, Figure 1).
The crude event rates for sMI (n = 731) alone per increasing quar-
tile groups of IL-18 were 4.5%, 4.7%, 4.0%, and 4.4%. There was no
association between the IL-18 level and sMI: HR 0.99 (95% CI
0.95-1.03) (Figure 1). Neither was there any relationship between
non-CABG major bleeding (n = 602) and increasing quartile group of
IL-18 levels: 3.8%, 3.6%, 3.4%, and 3.6%, respectively; HR 0.96 (95%
CI 0.91-1.00) (P value = 0.06).
TABLE 3 Multivariable Cox regression analysis, and event rates, on baseline IL-18 (ng/L) and CV death during up to 1 year of follow-up
(n = 16 636)a
Model IL-18 level No of events No of patients Crude event rate (%) HR (95% CI) P value
Model 1a Continuous 677 16 636 4.1 1.10 (1.06-1.14) <.0001
Model 1b <Q1: <180.0 132 4176 3.2 <.0001
Q1-<Q2: 180.0-237.0 143 4174 3.4 1.09 (0.86-1.38)
Q2-<Q3: 237.0-311.0 180 4118 4.4 1.41 (1.12-1.76)
≥Q3: ≥311.0 222 4168 5.3 1.73 (1.40-2.15)
Model 2a Continuous 665 16 577 4.0 1.09 (1.05-1.13) <.0001
Model 2b <Q1: <180.0 130 4161 3.1 <.0001
Q1-<Q2: 180.0-237.0 140 4162 3.4 1.09 (0.86-1.39)
Q2-<Q3: 237.0-311.0 177 4102 4.3 1.45 (1.15-1.82)
≥Q3: ≥311.0 218 4152 5.3 1.63 (1.31-2.04)
Model 3a Continuous 658 16 139 4.1 1.06 (1.02-1.10) .0019
Model 3b <Q1: <180.0 128 4052 3.2 .0169
Q1-<Q2: 180.0-237.0 138 4057 3.4 1.07 (0.84-1.36)
Q2-<Q3: 237.0-311.0 175 4008 4.4 1.32 (1.05-1.67)
≥Q3: ≥311.0 217 4022 5.4 1.36 (1.08-1.71)
Model 4a Continuous 571 14 488 3.9 1.04 (1.00-1.08) .0645
Model 4b <Q1: <180.0 112 3660 3.1 .2917
Q1-<Q2: 180.0-237.0 123 3685 3.3 1.02 (0.79-1.32)
Q2-<Q3: 237.0-311.0 152 3598 4.2 1.20 (0.94-1.54)
≥Q3: ≥311.0 184 3545 5.2 1.19 (0.93-1.52)
Notes: Model 1 includes ln(IL-18) and randomized treatment. Model 2 includes ln(IL-18) and clinical variables. Model 3 includes the covariates from Model 2
and biomarkers: ln(cystatin C), ln(cTnT-hs), ln(NT-proBNP). Model 4 includes the covariates from Model 3 and biomarkers: ln(CRP), ln(GDF-15), and ln(WBC).
aQuartile groups IL-18: Q1; <180, Q2; 181-236, Q3; 237-311, Q4; 312.
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3.3 | Interaction between IL-18 and the effects of
randomized treatment on outcome
There was no significant interaction between the IL-18 quartile
groups and the effects on outcomes by the randomized treatment.
The associations between IL-18 levels and the effects of randomized
treatment (ticagrelor vs clopidogrel) were also investigated by
restricted cubic splines (Figure S1A, B, C and D). There were similar
associations between IL-18 levels and outcomes irrespective of treat-
ment with ticagrelor or clopidogrel, except for sMI where there was a
trend for increasing events with increasing IL-18 level in the
clopidogrel group but not the ticagrelor group.
3.4 | IL-18 concentrations and variables associated
with IL-18 concentrations during follow-up
Patients with a baseline IL-18 sample and at least one subsequent
follow-up sample (at discharge, 1 month, or 6 months) were included in
the serial biomarker subset (n = 4583) (Table 4). There was a significant
increase in IL-18 concentrations during the first month, with a similar
level at 1 and 6 months after the index event in ACS survivors (Table 4).
The increase in IL-18 concentrations was observed irrespective of ran-
domized treatment (Table 4).
The following variables were significantly associated with the IL-18
concentration at three out of the four occasions during follow-up: male
sex, obesity, diabetes and biomarkers of renal function (cystatin C), and
inflammation (WBC, CRP-hs, GDF-15, Il-10) (Table S1).
4 | DISCUSSION
The main findings of the current study were that, in patients with
ACS, the IL-18 concentration increased during 1 month after the
acute event and remained at around the same level for at least
6 months. Higher IL-18 levels were consistently associated with male
sex, higher BMI, diabetes, decreased renal function, and other inflam-
matory biomarkers. The IL-18 level at baseline was significantly asso-
ciated with CV mortality independent of clinical characteristics and
indicators of renal and cardiac dysfunction. However, the association
with CV mortality was attenuated and did not remain statistically sig-
nificant after further adjustment with biomarkers, including GDF-15
and inflammatory markers. Finally, there was no association between
IL-18 level and the risk of myocardial infarction.
Inflammation is an important factor for the development of athero-
sclerosis, coronary plaques, and plaque rupture.1,13,14 A large number of
inflammatory markers have been described, and IL-18 has been reported
associated with both presence of CV disease and clinical outcomes.6,7
However, the exact role of these inflammatory mediators in ACS is com-
plex and the importance of IL-18 is only partly understood. The predictive
accuracy of these markers can be influenced by the clinical context and
the sample time, which is not always well recorded, and consequently the
levels of an inflammatory marker prior to an event, including IL-18, is dif-
ficult to estimate.14,15 As might be expected, in the current study of
patients with ACS, levels of IL-18 increased from the first measurement
at baseline to discharge.16 Further, the concentrations remained elevated
from 1 month until the last observation at 6 months. These findings sug-
gest that the inflammatory response by IL-18 to ACS is rapid but the pos-
sible return to pre-ACS levels is slow, as if or when it returns to baseline
is currently unknown. In comparison, CRP-hs and WBC have a much
faster regression, tapering within days.
The prognostic impact of IL-18 has previously been examined in a
smaller cohort (n = 1261) of patients with ACS, which also showed a
significant association with long-term (10 years) overall mortality but
not with MI.8 In our study, comprising a more than 10 times larger
cohort of patients with ACS, the overall mortality was 5.6% of which
the vast majority was CV deaths. An association between the IL-18
levels and CV mortality was also observed and, importantly, the associ-
ation between IL-18 and CV death remained significant even after the
TABLE 4 Median IL-18 concentrations (ng/L) during follow-up: at baseline, discharge and after 1 and 6 monthsa
Visit
Overall Ticagrelor Clopidogrel
N
Median IL-18
(ng/L; Q1-Q3) P value N
Median IL-18
(ng/L; Q1;Q3) N
Median IL-18
(ng/L; Q1;Q3)
P value
(rand. treatment)
Baseline 4585 233 (179-306) 2277 232 (179-306) 2306 233 (179-305)
Discharge 4461 284 (216-369) 2211 284 (215-367) 2245 283 (217-370)
Change from baseline 4461 46 (2-97) <.0001 2211 46 (1-95) 2245 47 (4-99) .2471
1 month 3982 306 (233-395) 1982 304 (232-395) 2000 308 (234-396)
Change from baseline 3982 72 (17-132) <.0001 1982 68 (15-129) 2000 76 (18-135) .1255
Change from discharge 3859 25 (−34-84) <.0001
6 months 1929 320 (244-414) 937 323 (245-414) 992 318 (243-413)
Change from baseline 1929 80 (28-142) <.0001 937 79 (26-141) 992 81 (30-144) .7980
Change from discharge 1856 35 (−23-96) <.0001
Change from 1 month 1907 17 (−43-80) <.0001
aTo the left presented overall and to the right in strata by randomized treatment. All subjects with a baseline value and at least one follow-up sample were
included in the analysis (n = 4583). The model includes a non-parametric test with the baseline value as a covariate.
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adjustment for important CV risk markers as cystatin C, NT-proBNP,
and cTnT-hs.
But after the addition of inflammatory biomarkers, this association
was no longer statistically significant. This clearly indicates that inflam-
matory activity is a contributing factor to fatal CV events beyond the
risk associated with clinical variables and cardiorenal biomarkers. The
attenuation of the association after the adjustment also for other
inflammatory markers like CRP-hs, WBC, and CV risk marker GDF-15
may hypothesize that these markers share common pathways of the
underlying inflammation in patients with ACS. Thus, although the prog-
nostic importance of IL-18 is limited if other inflammatory biomarkers
are available, IL-18 may still indicate important underlying processes
contributing to fatal outcomes in ACS. Additionally, one should not rule
out that a biomarker, still associated with outcome after adjustment for
important biomarkers cystatin C, NT-proBNP, and cTnT-hs, may pro-
vide important information in certain subgroups or cohorts.17
The biological function of IL-18 includes the induction of several
pro-inflammatory mediators like the cytokines interferon-gamma
(IFN-γ), IL-1β, and IL-6.18 IL-18 has also been proposed to activate cir-
culating monocytes that eventually can transform into foam cells, the
hallmark cell in atherosclerosis.1,13 The production of IL-18 is regu-
lated by the inflammasome, a complex of intracellular signal proteins,
that modifies the inflammatory response.18,19 Human macrophages
and endothelial cells express IL-18 receptors and activation of these
receptors induce the production of mediators with defined roles in
thrombosis and atherogenesis, including IL-6 and intracellular adhe-
sion molecule (ICAM)-1.5 Consequently, the intricate activation and
multiple features of the pleiotropic cytokine IL-18 can result in a
broad variety of responses.3,18 Despite the proposed role of IL-18 in
atherogenesis and thrombosis, we did not find IL-18 concentrations
to be associated with sMI in the present study. Further investigations
into the underlying mechanisms for this association, for example, asso-
ciation to individual causes of death such as congestive heart failure or
arrhythmic death, might yield additional important information.
We have previously reported that clopidogrel treatment, compared
with ticagrelor treatment, was associated with a higher incidence of
severe pulmonary infections or sepsis and an increased mortality.20 This
finding was accompanied with a lower leucocyte count at one month
and lower mean CRP-hs and IL-6 concentrations in patients random-
ized to clopidogrel, indicating possible effects of the randomized anti-
platelet treatment on immune signaling.20 However, we found no
evidence that the randomized antiplatelet treatment affected IL-18
concentrations. Rather, an enhanced and sustained inflammatory
response for more than 6 months after ACS was observed, irrespective
of randomized antiplatelet treatment.
5 | LIMITATIONS
The PLATO trial enrolled a broad ACS population but, as in several
clinical trials, certain patient groups were excluded, for example,
patients requiring dialysis or patients with recent significant bleeding.
The current substudy investigated IL-18 concentrations at baseline, and
all samples were drawn within 24 h of admission, nonetheless, the time
span between symptom onset and sample time is not adjusted for and
may have affected the observed IL-18 results at baseline. Further, the
reported IL-18 concentrations were circulating IL-18, and we were not
able to either measure or estimate total IL-18 levels.
6 | CONCLUSION
In patients with ACS, the IL-18 concentration increased during the first
month after the acute event and remained at similar level at 6 months.
The IL-18 levels were consistently associated with male sex, higher BMI,
diabetes, decreased renal function, and to other inflammatory biomarkers.
The IL-18 level at baseline was significantly associated with CV-mortality
independent of clinical characteristics and indicators of renal and cardiac
dysfunction. However, the association with CV mortality was attenuated
and did not remain statistically significant after the adjustment for further
inflammatory biomarkers and GDF-15. Although the prognostic impor-
tance of IL-18 is limited if other prognostic inflammatory biomarkers are
available, IL-18may still be part of underlying inflammatory processes con-
tributing to fatal outcomes in ACS.
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